Table 1.

Patient data

Patient no.Age, y/ sexDisease duration, yWeaknessSensory lossPrior therapyNCS patternM protein/ Ab targetStrength change*Total IgM, mg%IgM antibody titer
Pre-RxPost-RxPre-RxPost-Rx
* Increase (as a percentage of normal strength) in distal muscles from month 0, immediately before treatment, to final measurement at month 3 or 6.
† Antibody titer against GM1 ganglioside.
‡ Antibody titer against MAG.
IVIg = intravenous immunoglobulin; PE = plasma exchange; NCS = nerve conduction study; NCV = nerve conduction velocity; Ab = antibody; GM1 = GM1 ganglioside; MAG = myelin-associated glycoprotein; Rx = treatment.
152 /M14Asymmetric, distal arms and legsoneIVIg, PE and CytoxanDemyelination, conduction block; axonal lossIgM λ, GM1+16%1549760,50038,000, 6 mo
244 /M4Asymmetric, distal arms and legsNoneIVIg, PE and CytoxanDemyelination, conduction block; axonal lossIgM λ, GM1+18%44642323,00011,000, 6 mo
351 /M10Asymmetric, distal arms and legsNonePE and CytoxanDemyelination, conduction block; axonal lossNone, GM1+22%2611,030700, 3 mo
451 /M12Asymmetric, distal arms and legsNoneIVIg, PE and CytoxanDemyelination, conduction block; axonal lossNone, GM1+19%59513,0002,500, 3 mo
568 /F9Symmetric, distal legsLarge and small fiberIVIg, PE and Cytoxan, steroidsDemyelination, slow NCV; axonal lossIgM κ, MAG+37%631322261,000130,000, 6 mo